ABT
Abbott Laboratories
NYSE: ABT · HEALTHCARE · MEDICAL DEVICES
$88.18
-1.64% today
Updated 2026-06-12
Market cap
$151.49B
P/E ratio
24.36
P/S ratio
3.36x
EPS (TTM)
$3.57
Dividend yield
2.78%
52W range
$82 – $136
Volume
12.2M
WallStSmart proprietary scores
56
out of 100
Grade: C+
Hold
Investment rating
4.0
Growth
C6.0
Quality
B6.0
Profitability
B4.7
Valuation
C4/9
Piotroski F-Score
Moderate
2.7
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$137.71
+56.17%
12-Month target
$103.22
+17.06%
Intrinsic (DCF)
$70.89
Margin of safety
-28.47%
4 Strong Buy16 Buy7 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $916.00M — positive
Risks
- 28.47% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $43.65B | $40.11B | $41.95B | $44.33B | $45.13B | $48.8B |
| Net income | $6.93B | $5.72B | $13.40B | $6.52B | $1.08B | — |
| EPS | — | — | — | — | $3.57 | $5.74 |
| Free cash flow | $7.80B | $5.06B | $6.35B | $7.39B | $916.00M | — |
| Profit margin | 15.88% | 14.27% | 31.95% | 14.72% | 13.90% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-28 | MORELAND, MARY K | Buy | 5,314 | $94.41 |
| 2026-04-27 | STARKS, DANIEL J | Buy | 10,000 | $92.65 |
| 2026-04-24 | STRATTON, JOHN G | Buy | 2,286 | — |
Peer comparison
Smart narrative
Abbott Laboratories trades at $88.18. representing a P/E of 24.36x trailing earnings. Our Smart Value Score of 56/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 2.71, it sits in the grey zone. TTM revenue stands at $45.13B. with profit margins at 13.90%. Our DCF model estimates intrinsic value at $70.89.
Frequently asked questions
What is Abbott Laboratories's stock price?
Abbott Laboratories (ABT) trades at $88.18, on a P/E of 24.4x and a P/S of 3.4x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Abbott Laboratories overvalued?
Abbott Laboratories carries a Smart Value Score of 56/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $70.89 against the $88.18 price, so on cash flow terms the market is paying a premium for Abbott Laboratories's growth. The Hold rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Abbott Laboratories (ABT)?
The 12-month analyst consensus target is $137.71, about 56.2% above the current $88.18. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of ABT by 2030?
Our research-backed model puts the 2030 base case at $462.92, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Abbott Laboratories (ABT)?
Our DCF model estimates intrinsic value at $70.89, a -28.5% margin of safety versus today's $88.18. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Abbott Laboratories's revenue?
Abbott Laboratories's trailing twelve-month revenue is $45.13B, and our model projects it reaching about $66.10B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Abbott Laboratories's Altman Z-Score is 2.71, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio3.36x
ROE12.06%
Beta0.65
50D MA$93.45
200D MA$116.17
Shares out1.74B
Float1.73B
Short ratio—
Avg volume12.2M
Performance
1 week+0.00%
1 month+7.81%
3 months-16.66%
YTD-27.31%
1 year—
3 years—
5 years—